Massive re rate coming for GTG in 2021, page-6

Experienced CEO in the medical industry??

Let's be clear, OTC products are more like retail than Pharma/medical products, and this business model is based on price points into the major chains.

He left Blackmores before the huge share increase, mainly due to the update in China, and Sanofi have such as range into OTC that most of the work is at these price points.
He wasn't selling prescription medicine or Vaccines, which require clinician involvement.

In essence, he has no Medical experience, no background in Pathology, no in-licensing/out-licensing experience and no Governmental/Medicare Benefit Schedule Experience....all of which are vital to this company and its products. His experience is in OTC and his consulting has been in the Retail area.....Why is he leaving his consulting position if he is that successful and has numerous industry contacts.....

They would have been better off employing an 'experienced' CEO with Pathology background, who understands that for a rebate-able service (MBS) that this will require clinician involvement....unless they believe that they will go direct to patient, which will mean lower margins as Chemist Warehouse etc will ensure they make their margin.

This appointment, to me, at least, smacks of George et al signing a 'yes man' for George to continue to run the company....which in the past has been disappointing to say the least.

This market will become extremely large.....the number of players is starting to become like the Medicinal Cannabis Industry....it will need to consolidate, and if so, the number of shares in GTG will prevent any 'real' profit for shareholders, except for George and Mark.